Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

Abstract

The recommended dose for phase II studies is 8.4 mg/m2 when administered as a 24-hour infusion, which is well tolerated. Further studies will be necessary to account for the putative nonlinear behavior of the drug.